Skip to content
Biodatica
Start free

Juno Therapeutics, a Subsidiary of Celgene

Los Angeles, California

OncologyPhase IIListed · BMY

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase I trial registered: A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma

5mo agoTrial registeredFeb 9, 2026Source filing (opens the source filing in a new tab)

Momentum

69no change

Momentum 69 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    Study registered

    Dec 11, 2025

    Lymphoma, Large B-Cell, Diffuse · AVAILABLE · sponsor: Juno Therapeutics, a Subsidiary of Celgene · Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol

    ClinicalTrials.gov · NCT04400591 (opens the source filing in a new tab)

  2. Trial

    PHASE1 registered

    Feb 24, 2021

    Multiple Myeloma · COMPLETED · sponsor: Juno Therapeutics, a Subsidiary of Celgene · A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma

    ClinicalTrials.gov · NCT04674813 (opens the source filing in a new tab)

  3. Trial

    PHASE2 registered

    Nov 29, 2018

    Lymphoma, Non-Hodgkin, Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Neoplasms by Histologic Type, Lymphoproliferative Disorders, Lymphatic Diseases, Immunoproliferative Disorders, Immune System Disorder · COMPLETED · sponsor: Juno Therapeutics, a Subsidiary of Celgene · A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)

    ClinicalTrials.gov · NCT03744676 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources